Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension.
暂无分享,去创建一个
G. Visner | Hanzhong Liu | S. Kourembanas | S. A. Mitsialis | H. Christou | Li Liu | Yong-guang Xiao | S. Mitsialis
[1] A. De Luca,et al. Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. , 2013, American journal of respiratory and critical care medicine.
[2] G. Visner,et al. Indoleamine 2,3-dioxygenase and metabolites protect murine lung allografts and impair the calcium mobilization of T cells. , 2012, American journal of respiratory cell and molecular biology.
[3] Yunchao Su,et al. Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. , 2011, The Journal of clinical investigation.
[4] S. Provencher,et al. Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension , 2011, Respiratory research.
[5] Howard Y. Chang,et al. Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. , 2011, The Journal of clinical investigation.
[6] H. Ghofrani,et al. Mechanisms of disease: pulmonary arterial hypertension , 2011, Nature Reviews Cardiology.
[7] O. Liang,et al. Early Macrophage Recruitment and Alternative Activation Are Critical for the Later Development of Hypoxia-Induced Pulmonary Hypertension , 2011, Circulation.
[8] K. Stenmark,et al. Cell-based therapies in pulmonary hypertension: who, what, and when? , 2011, American journal of physiology. Lung cellular and molecular physiology.
[9] E. Paquet,et al. Role for miR-204 in human pulmonary arterial hypertension , 2011, The Journal of experimental medicine.
[10] W. Seeger,et al. Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling , 2010, PloS one.
[11] E. Michelakis,et al. The role of mitochondria in pulmonary vascular remodeling , 2010, Journal of Molecular Medicine.
[12] E. K. Weir,et al. Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.
[13] J. Stasch,et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation , 2010, Nature Medicine.
[14] G. Visner,et al. Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression1 , 2009, The Journal of Immunology.
[15] P. Thistlethwaite,et al. Development and pathology of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[16] Jie Liu,et al. Modulation of pulmonary vascular smooth muscle cell phenotype in hypoxia: role of cGMP-dependent protein kinase and myocardin. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[17] C. Mah,et al. Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapy-treated hemophilia A mice , 2009, Gene Therapy.
[18] David A. Williams. Sleeping beauty vector system moves toward human trials in the United States. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[19] G. Prendergast,et al. Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape , 2008, Immunological reviews.
[20] Joan M. Taylor,et al. The Histone Demethylase, Jmjd1a, Interacts With the Myocardin Factors to Regulate SMC Differentiation Marker Gene Expression , 2007, Circulation research.
[21] G. Visner,et al. Nonviral Gene Delivery With Indoleamine 2,3‐Dioxygenase Targeting Pulmonary Endothelium Protects Against Ischemia‐Reperfusion Injury , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[22] S. Erzurum,et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[23] S. Archer,et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted , 2007, Proceedings of the National Academy of Sciences.
[24] G. Visner,et al. Applications of Sleeping Beauty transposons for nonviral gene therapy , 2007, IUBMB life.
[25] G. Visner,et al. Sleeping Beauty‐mediated eNOS gene therapy attenuates monocrotaline‐induced pulmonary hypertension in rats , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] G. Visner,et al. Sleeping Beauty‐based gene therapy with indoleamine 2,3‐dioxygenase inhibits lung allograft fibrosis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] B. Y. Chin,et al. Carbon monoxide reverses established pulmonary hypertension , 2006, The Journal of experimental medicine.
[28] G. Semenza,et al. Hypoxia Inducible Factor 1 Mediates Hypoxia-Induced TRPC Expression and Elevated Intracellular Ca2+ in Pulmonary Arterial Smooth Muscle Cells , 2006, Circulation research.
[29] G. Visner,et al. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. , 2006, American journal of respiratory and critical care medicine.
[30] N. Terada,et al. Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension , 2006, Laboratory Investigation.
[31] Eon J. Rios,et al. Chronic hypoxia elevates intracellular pH and activates Na+/H+ exchange in pulmonary arterial smooth muscle cells. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[32] W. Seeger,et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.
[33] S. Archer,et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.
[34] E. Raz,et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. , 2004, The Journal of clinical investigation.
[35] L. Notterpek,et al. Endothelial targeting of the Sleeping Beauty transposon within lung. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] G. Owens,et al. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. , 2004, Physiological reviews.
[37] Da-Zhi Wang,et al. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression , 2004, Nature.
[38] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[39] B. Baban,et al. Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion1 , 2003, The Journal of Immunology.
[40] J. Dyck,et al. Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels , 2002, Circulation.
[41] C. Hsieh,et al. Prevention of Hypoxia-Induced Pulmonary Hypertension by Enhancement of Endogenous Heme Oxygenase-1 in the Rat. • 238 , 1997, Pediatric Research.